The SUSTAIN and STEP trial series for semaglutide demonstrated 1015% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM: The SURMOUNT-1 trial for tirzepatide demonstrated up to 20.9% weight reduction at the highest dose (Jastreboff et al., 2022, NEJM: Retatrutide Phase II data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss, the highest reported for any pharmacological intervention in a randomised trial at the time of publication
Most people take Release between 3 and 6 months
Liquid or pureed diets during flare-ups
Understanding the expected timeline for GLP-1 medication effects is essential for setting realistic expectations and avoiding premature discontinuation
Lee, D.-H., Stangel, M., Gold, R